COVID-19 in early 2021: current status and looking forward

Chengdi Wang, Zhoufeng Wang, Guangyu Wang, Johnson Yiu-Nam Lau, Kang Zhang, Weimin Li, Chengdi Wang, Zhoufeng Wang, Guangyu Wang, Johnson Yiu-Nam Lau, Kang Zhang, Weimin Li

Abstract

Since the first description of a coronavirus-related pneumonia outbreak in December 2019, the virus SARS-CoV-2 that causes the infection/disease (COVID-19) has evolved into a pandemic, and as of today, >100 million people globally in over 210 countries have been confirmed to have been infected and two million people have died of COVID-19. This brief review summarized what we have hitherto learned in the following areas: epidemiology, virology, and pathogenesis, diagnosis, use of artificial intelligence in assisting diagnosis, treatment, and vaccine development. As there are a number of parallel developments in each of these areas and some of the development and deployment were at unprecedented speed, we also provided some specific dates for certain development and milestones so that the readers can appreciate the timing of some of these critical events. Of note is the fact that there are diagnostics, antiviral drugs, and vaccines developed and approved by a regulatory within 1 year after the virus was discovered. As a number of developments were conducted in parallel, we also provided the specific dates of a number of critical events so that readers can appreciate the evolution of these research data and our understanding. The world is working together to combat this pandemic. This review also highlights the research and development directions in these areas that will evolve rapidly in the near future.

Conflict of interest statement

J.Y.-N.L. has an equity position in Avalon Biomedical Management, which has research projects related to SARS-CoV-2 diagnostics and COVID-19 vaccine development. K.Z. filed patents on COVID-19 diagnosis and vaccines. The other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Immunopathogenesis of coronavirus disease 2019 (COVID-19) in early and advanced stage
Fig. 2
Fig. 2
Illustration of network architectures of the proposed AI diagnostic system for COVID-19

References

    1. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
    1. World Health Organization. Coronavirus Disease (COVID-2019) Situation Reports (World Health Organization, 2020).
    1. Li Q, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 2020;382:1199–1207. doi: 10.1056/NEJMoa2001316.
    1. Chan JF-W, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523. doi: 10.1016/S0140-6736(20)30154-9.
    1. Holshue ML, et al. First case of 2019 Novel Coronavirus in the United States. N. Engl. J. Med. 2020;382:929–936. doi: 10.1056/NEJMoa2001191.
    1. Anfinrud P, Stadnytskyi V, Bax CE, Bax A. Visualizing speech-generated oral fluid droplets with laser light scattering. N. Engl. J. Med. 2020;382:2061–2063. doi: 10.1056/NEJMc2007800.
    1. van Doremalen N, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N. Engl. J. Med. 2020;382:1564–1567. doi: 10.1056/NEJMc2004973.
    1. Huang R, Xia J, Chen Y, Shan C, Wu C. A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China. Lancet Infect. Dis. 2020;20:534–535. doi: 10.1016/S1473-3099(20)30147-X.
    1. Xu Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat. Med. 2020;26:502–505. doi: 10.1038/s41591-020-0817-4.
    1. Hui, K. P. Y. et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir. Med.10.1016/s2213-2600(20)30193-4 (2020).
    1. Chen H, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395:809–815. doi: 10.1016/S0140-6736(20)30360-3.
    1. Qiu, H. et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect. Dis.10.1016/S1473-3099(20)30198-5 (2020).
    1. Chen T, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091.
    1. Giordano GA-O, et al. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. Nat. Med. 2020;26:855–860. doi: 10.1038/s41591-020-0883-7.
    1. Wang T, et al. A four-compartment model for the COVID-19 infection—implications on infection kinetics, control measures, and lockdown exit strategies. Precis. Clin. Med. 2020;3:104–112. doi: 10.1093/pcmedi/pbaa018.
    1. Gilbert M, Dewatripont M, Muraille E, Platteau JP, Goldman M. Preparing for a responsible lockdown exit strategy. Nat. Med. 2020;26:643–644. doi: 10.1038/s41591-020-0871-y.
    1. Centers for Disease Control and Prevention of USA (CDC). Symptoms of Coronavirus (COVID-19). (CDC US 2020).
    1. World Health Organization. Clinical Management of Severe Acute Respiratory Infection (SARI) When Covid-19 Disease is Suspected: Interim Guidance, 13 March 2020 (World Health Organization, 2020).
    1. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing. Xue Za Zhi. 2020;41:145–151.
    1. Wang M, et al. A precision medicine approach to managing 2019 novel coronavirus pneumonia. Precis. Clin. Med. 2020;3:14–21. doi: 10.1093/pcmedi/pbaa002.
    1. Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association. An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19) Zhonghua Liu Xing Bing. Xue Za Zhi. 2020;41:139–144.
    1. Zhang, K. et al. Significant reduction of humoral response to SARS-CoV-2 4 months after the diagnosis of COVID-19. Precis. Clin. Med.10.1093/pcmedi/pbaa036 (2020).
    1. Zhang K, Lau JY-N, Yang L, Ma Z-G. SARS-CoV-2 reinfection in two patients who have recovered from COVID-19. Precis. Clin. Med. 2020;3:292–293. doi: 10.1093/pcmedi/pbaa031.
    1. Vrieze, J. D. More people are getting COVID-19 twice, suggesting immunity wanes quickly in some. Science10.1126/science.abf7769 (2020).
    1. Verity, R. et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect. Dis.10.1016/S1473-3099(20)30243-7 (2020).
    1. Chen, Z.-M. et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J. Pediatr. 10.1007/s12519-020-00345-5 (2020).
    1. Hong, H., Wang, Y., Chung, H.-T. & Chen, C.-J. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. Pediatr. Neonatol. 10.1016/j.pedneo.2020.03.001 (2020).
    1. Dong, Y. et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics10.1542/peds.2020-0702 (2020).
    1. Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens. Care Med.10.1007/s00134-020-05991-x (2020).
    1. Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med.10.1001/jamainternmed.2020.0994 (2020).
    1. Deng, Y. et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin. Med. J.10.1097/CM9.0000000000000824 (2020).
    1. Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med.10.1016/S2213-2600(20)30079-5 (2020).
    1. Liu W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin. Med. J. 2020 doi: 10.1097/CM9.0000000000000775.
    1. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin. Chim. Acta. 2020;506:145–148. doi: 10.1016/j.cca.2020.03.022.
    1. CDC, U. Coronavirus Disease 2019 (COVID-19) Cases in the U.S. (2020).
    1. Team CC-R. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. Morb. Mortal. Wkly Rep. 2020;69:343–346. doi: 10.15585/mmwr.mm6912e2.
    1. Arentz, M. et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA10.1001/jama.2020.4326 (2020).
    1. McMichael, T. M. et al. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N. Engl. J. Med. 10.1056/NEJMoa2005412 (2020).
    1. Mahase E. Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ. 2020;368:m641. doi: 10.1136/bmj.m641.
    1. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368:860–868. doi: 10.1126/science.abb5793.
    1. Chen S, et al. Fangcang shelter hospitals: a novel concept for responding to public health emergencies. Lancet. 2020;395:1305–1314. doi: 10.1016/S0140-6736(20)30744-3.
    1. Zhang J, et al. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. Science. 2020;368:1481–1486. doi: 10.1126/science.abb8001.
    1. Greenhalgh, T., Schmid, M. B., Czypionka, T., Bassler, D. & Gruer, L. Face masks for the public during the covid-19 crisis. BMJ369, 10.1136/bmj.m1435 (2020).
    1. Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc. Natl Acad. Sci. USA. 2020;117:9241–9243. doi: 10.1073/pnas.2004999117.
    1. Lu R, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8.
    1. Yan R, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448. doi: 10.1126/science.abb2762.
    1. Zou, X. et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 10.1007/s11684-020-0754-0 (2020).
    1. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am. J. Respir. Crit. Care Med. 2020;201:1557–1559. doi: 10.1164/rccm.202003-0693LE.
    1. Coutard B, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir. Res. 2020;176:104742. doi: 10.1016/j.antiviral.2020.104742.
    1. Hanff, T. C., Harhay, M. O., Brown, T. S., Cohen, J. B. & Mohareb, A. M. Is there an association between COVID-19 mortality and the renin-angiotensin system-a call for epidemiologic investigations. Clin. Infect. Dis.10.1093/cid/ciaa329 (2020).
    1. Horby, P. et al. NERVTAG Paper on COVID-19 Variant of Concern B.1.1.7 (Crown Copyright, 2021).
    1. Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife9, 10.7554/eLife.61312 (2020).
    1. Resende, P. C. et al. Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil. (2021).
    1. Liu X, et al. General observation report on system anatomy of dead corpses of COVID-2019 pneumonia. J. Forensic Med. 2020;36:21–23.
    1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–793. doi: 10.1001/jama.2020.12839.
    1. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020;22:74–79. doi: 10.1016/j.micinf.2020.01.003.
    1. Yang, Y. et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. Preprint at medRxiv10.1101/2020.02.11.20021493 (2020).
    1. To, K. K.-W. et al. Consistent detection of 2019 novel coronavirus in saliva. Clin. Infect. Dis. 10.1093/cid/ciaa149 (2020).
    1. Ni L, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52:971–977. doi: 10.1016/j.immuni.2020.04.023.
    1. Xu X, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat. Med. 2020;26:1193–1195. doi: 10.1038/s41591-020-0949-6.
    1. World Health Organization. Laboratory Testing for Coronavirus Disease (COVID-19) in Suspected Human Cases: Interim Guidance, 19 March 2020 (World Health Organization, Geneva, 2020).
    1. Guo, L. et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin. Infect. Dis.10.1093/cid/ciaa310 (2020).
    1. To, K. K.-W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis.10.1016/S1473-3099(20)30196-1 (2020).
    1. Sun P, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J. Med. Virol. 2020;92:612–617. doi: 10.1002/jmv.25735.
    1. Li Z, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J. Med. Virol. 2020 doi: 10.1002/jmv.25727.
    1. Chen C, et al. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): a systematic review and meta-analysis. Int. J. Infect. Dis. 2021;104:458–464. doi: 10.1016/j.ijid.2021.01.017.
    1. Zhang K, et al. Clinically applicable AI system for accurate diagnosis, quantitative measurements, and prognosis of COVID-19 pneumonia using computed tomography. Cell. 2020;181:1423–1433 e1411. doi: 10.1016/j.cell.2020.04.045.
    1. Mei X, et al. Artificial intelligence-enabled rapid diagnosis of patients with COVID-19. Nat. Med. 2020;26:1224–1228. doi: 10.1038/s41591-020-0931-3.
    1. Ting DSW, Carin L, Dzau V, Wong TY. Digital technology and COVID-19. Nat. Med. 2020;26:459–461. doi: 10.1038/s41591-020-0824-5.
    1. Alimadadi A, et al. Artificial intelligence and machine learning to fight COVID-19. Physiol. Genomics. 2020;52:200–202. doi: 10.1152/physiolgenomics.00029.2020.
    1. Kamel Boulos MN, Geraghty EM. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemics. Int. J. Health Geogr. 2020;19:8. doi: 10.1186/s12942-020-00202-8.
    1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 2020 doi: 10.1016/S1473-3099(20)30120-1.
    1. Xu X-W, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi: 10.1136/bmj.m606.
    1. Chen, Z. et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Preprint at medRxiv10.1101/2020.03.22.20040758 (2020).
    1. Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob Agents10.1016/j.ijantimicag.2020.105949 (2020).
    1. Mitjà O, et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N. Engl. J. Med. 2021;384:417–427. doi: 10.1056/NEJMoa2021801.
    1. Horby P, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med. 2020;383:2030–2040. doi: 10.1056/NEJMoa2022926.
    1. Rosenberg ES, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323:2493–2502. doi: 10.1001/jama.2020.8630.
    1. FDA. Hydroxycholoquine and Chloroquine Letter (FDA, 2020).
    1. Falzarano D, et al. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci. Rep. 2013;3:1686. doi: 10.1038/srep01686.
    1. Hung IF, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–1704. doi: 10.1016/S0140-6736(20)31042-4.
    1. Young, B. E. et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA10.1001/jama.2020.3204 (2020).
    1. Kujawski SA, et al. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat. Med. 2020;26:861–868. doi: 10.1038/s41591-020-0877-5.
    1. Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA10.1001/jama.2020.4783 (2020).
    1. Roback, J. D. & Guarner, J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA10.1001/jama.2020.4940 (2020).
    1. Liao M, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020;26:842–844. doi: 10.1038/s41591-020-0901-9.
    1. Zhao J, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Chin. J. Tuberculosis Respir. Dis. 2020;43:183–184.
    1. National Institutes of Health & Elvey, M. The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19. Technical Report (National Institutes of Health, 2021).
    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. doi: 10.1016/S0140-6736(20)30317-2.
    1. Horby P, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N. Engl. J. Med. 2020;384:693–704.
    1. Guan, W.-J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med.10.1056/NEJMoa2002032 (2020).
    1. Alhazzani, W. et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intens. Care Med.10.1007/s00134-020-06022-5 (2020).
    1. Ramanathan K, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir. Med. 2020 doi: 10.1016/S2213-2600(20)30121-1.
    1. Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.
    1. Gao, Q. et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science10.1126/science.abc1932 (2020).
    1. Choi YH, et al. Renal replacement therapy is independently associated with a lower risk of death in patients with severe acute kidney injury treated with targeted temperature management after out-of-hospital cardiac arrest. Crit. Care. 2020;24:115. doi: 10.1186/s13054-020-2822-x.
    1. Zhu FC, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488. doi: 10.1016/S0140-6736(20)31605-6.
    1. Logunov DY, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887–897. doi: 10.1016/S0140-6736(20)31866-3.
    1. Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. doi: 10.1016/S0140-6736(20)31604-4.
    1. Xia S, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324:951–960. doi: 10.1001/jama.2020.15543.
    1. Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N. Engl. J. Med.10.1056/NEJMoa2022483 (2020).
    1. Anderson, E. J. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 10.1056/NEJMoa2028436 (2020).
    1. Mulligan MJ, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–593. doi: 10.1038/s41586-020-2639-4.
    1. Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 10.1056/NEJMoa2027906 (2020).
    1. Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.
    1. Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.
    1. Kirby, J. Israel outpaced the world in vaccinations. Now it’s seeing the results. Vox (2021). .
    1. Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N. Engl. J. Med. 2020;384:643–649. doi: 10.1056/NEJMra2035343.
    1. Jeyanathan M, et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 2020;20:615–632. doi: 10.1038/s41577-020-00434-6.
    1. Ramasamy MN, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–1993. doi: 10.1016/S0140-6736(20)32466-1.
    1. Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1.
    1. Zhu FC, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854. doi: 10.1016/S0140-6736(20)31208-3.
    1. Hu, Y. & Liu, C. CanSino says its COVID-19 vaccine has no serious adverse events, meets efficacy criteria in interim analysis. Global Times (2021). .
    1. Logunov DY, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–681. doi: 10.1016/S0140-6736(21)00234-8.
    1. Xia S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 2021;21:39–51. doi: 10.1016/S1473-3099(20)30831-8.
    1. Zhang Y, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021;21:181–192. doi: 10.1016/S1473-3099(20)30843-4.
    1. Keech C, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 2020;383:2320–2332. doi: 10.1056/NEJMoa2026920.
    1. Yang J, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586:572–577. doi: 10.1038/s41586-020-2599-8.
    1. CDC US. Myths and Facts About COVID-19 Vaccines (CDC US, 2021).
    1. Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature10.1038/s41586-021-03291-y (2021).

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner